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Abstract
Objective To evaluate whether collagenase injections 
would be a cost-effective alternative to surgery for 
Dupuytren’s contracture in Malta. 
Method An average of fifty patients per year requires 
surgery to correct Dupuytren’s contracture in Malta. The 
price of collagenase injections was obtained from published 
pharmacoeconomic studies in Spain, United Kingdom and 
United States. The cost to treat multiple affected joints 
using collagenase injections at the different prices was 
compared to the costs associated with surgery in both 
the government and private hospital setting. A proposed 
price at which collagenase injections would be more cost-
effective than surgery to treat two affected joints in Malta 
was calculated. 
Key findings The cost of surgery in the private 
hospital setting is significantly higher than that in the 
government hospital setting. The price of collagenase in the 
United States is significantly higher than in Europe. At the 
prices available in Europe, collagenase use in Malta would 
not confer significantly increased costs when treating one, 
two or three affected joints, both in the government and 
private hospital setting. Treating two affected joints rather 
than one affected joint does not significantly increase 
costs, however treating three affected joints significantly 
increases costs, in both hospital settings. For collagenase 
injections to be cost-effective in Malta, they would need to 
be priced at 77 Euro per vial or less. 
Conclusion If all patients were to be administered 
the injection instead of undergoing surgery, the hospital 
would be able to accommodate 20 additional total knee 
replacements each year. With surgery costs in Malta being 
much less than in other European countries, there could 
be a possibility for Malta to attract patients from other 
countries. Collagenase injections would offer a less invasive 
treatment for the patients, and if priced at 77 Euro per vial 
or less, would provide a more cost-effective option to the 
government hospital.
Keywords Dupuytren’s contracture, collagenase, 
Clostridium histolyticum, open fasciectomy, costs
Introduction
Dupuytren’s Contracture (DC) is defined as a thickening of 
the fibrous tissue layer underneath the skin of the palm and 
fingers.1 The condition is not usually painful; however over 
time, the collagen thickening causes contracture, leading 
to the affected fingers becoming permanently flexed. A 
diagnosis of DC is usually made when there is a positive 
Hueston tabletop test, where the patient is unable to fully 
extend the fingers and place them flat on a surface.2
The first signs of Dupuytren’s Contracture are the formation 
of palpable collagen nodules in the palm of the hands. 
These collagen deposits tend to form collagen cords which 
usually extend longitudinally. Over time, the collagen 
thickens and shortens, causing the affected fingers to 
flex inwardly at the metacarpophalangeal joints or at the 
proximal interphalangeal joints. This contracture is usually 
irreversible.3,4
Various treatment options are available1,5; the most 
commonly used option is surgery, including partial or open 
fasciectomy.6,7 In 2010, the Food and Drug Administration 
(FDA) followed by the European Medicines Agency in 2011, 
approved the first pharmacological treatment to correct 
Dupuytren’s Contracture; an injection containing the enzyme 
collagenase Clostridium histolyticum (CCH). Collagenase 
injections are administered when there is a palpable cord, 
with a maximum of three injections given per cord at 
monthly intervals. Studies carried out concluded that CCH 
injections were a safe and effective alternative to surgery.3,8,9
It was estimated that in 2011 in England, DC related costs 
amounted to £41,576,141.10 Economic studies were carried 
out in the United Kingdom (UK)11, Spain12 and the United 
States (US).13 Studies undertaken in UK and Spain concluded 
that CCH injections, quoting the retail price of CCH injections 
at the time of the study, would reduce costs associated with 
treatment of DC.11,12 The study carried out in the US concluded 
that for CCH injections to be cost-effective, the price had to 
be one tenth of the retail price at the time of the study.13
The study carried out in Malta aimed to assess the cost-
effectiveness of CCH injections at the various prices available 
in other countries to the cost of open fasciectomy, both in 
the government and private hospital settings.
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1 joint 1011 2490 3138 7491
2 joints 1917 4875 6171 14877
3 joints 2823 7260 9204 22263
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Method
Determination of the most common procedure to correct DC 
used in Malta was undertaken through discussions with all 
orthopaedic surgeons. Open fasciectomy was costed both in 
the government hospital and private hospital setting. Costs 
included the salary of all the healthcare professionals, cost of 
drugs used, utility costs and equipment costs.
The prices of CCH injections were obtained from economic 
studies published in the UK, Spain and the US, and 
converted to Euro where necessary. The cost of treating 
multiple affected joints was calculated for each of the prices 
quoted and compared to surgery in both hospital settings. 
An assessment was undertaken to evaluate whether the 
introduction of CCH injections would be more cost-effective 
for the different settings when compared to surgery. 
A proposed price for CCH injections to be cost-effective in 
the Maltese healthcare system was calculated.
Results
Open fasciectomy at the government hospital costs €987 if 
performed under local anaesthesia and €1,196 if performed 
under general anaesthesia, including pre-operative tests, 
orthopaedic out-patient assessments and post-operative 
hand therapy sessions. The cost of surgery in a private 
hospital setting, including all the pre- and post-operative 
care is of €3,361. The cost of surgery in the private hospital 
setting is significantly higher than in the government 
hospital (p = 0.029).
The last known price of one vial of CCH injection was €725 
in Spain, £780 in the UK and $3,250 (actual price) and $315 
(proposed maximum price) in the US. These values were 
converted to Euro to enable comparison: €941 for the UK, 
€2392 actual price in the US and €232 proposed price in the 
US (as per exchange rate of 5 January 2014). The cost of CCH 
injections in the US is significantly higher than in Europe 
(p = 0.033). The proposed price for the US would significantly 
reduce the difference (p = 0.113).
Figures 1 and 2 show the cost of treating multiple affected 
joints with CCH injections at the different prices available, for 
the government hospital setting and for the private hospital 
setting respectively. At the prices available in the EU, the cost 
of using CCH injections was not significantly higher than 
surgery in both the government and private hospital setting 
when treating one (p = 0.112, 0.424), two (p = 0.09, 0.169) or 
three (p = 0.085, 0.118) affected joints. 
Figure 1: Cost of treating multiple affected joints in the government hospital setting at CCH prices available.
 
At €232 per 
vial 
At €725 per 
vial 
At €941 per 
vial 
At €2392 per 
vial 
1 joint 1146 2625 3273 7626
2 joints 2142 5100 6396 15102
3 joints 3138 7575 9519 22578
0
5000
10000
15000
20000
25000
C
o
st
 in
 E
u
ro
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hospital setting 
Figure 2: Cost of treating multiple affected joints in the private hospital setting at CCH prices available
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The cost increase to treat one additional joint at the prices 
available in Europe does not significantly increase the 
hospital’s expense in both the government and private 
hospital setting (p = 0.139, 0.129), both when comparing 
two joints over one, and three joints over two. The cost to 
treat two additional joints results in significantly higher costs 
(p = 0.024, 0.022).
The proposed price for CCH injections in Malta was calculated 
to be cost-effective when compared to surgery and aftercare 
to treat two affected fingers. With the majority of patients 
undergoing treatment at the government hospital, the 
surgical cost of €987 was taken as the maximum total cost. 
When taking into consideration the cost of required out-
patient visits, the proposed price was €77 per vial or less 
(Table 1).
Discussion
When comparing the cost of open fasciectomy in the 
government hospital setting to the cost of the same 
surgery in the private hospital setting, this difference in cost 
was proven to be statistically significant. Reasons for this 
are numerous, with the most important one being that the 
government hospital is fully subsidised by the government. 
In a private hospital setting, the hospital is dependent on 
the income it obtains from patients using its services to stay 
in business, pay bills, buy and maintain new equipment 
and at the same time, still offer a high standard of care. 
Medicines are purchased at the full price, not on tender, and 
no expense is subsidised by government funds.
The cost of treating one, two and three affected joints with 
CCH at European prices in the government hospital setting 
compared to the cost of open fasciectomy, showed that 
there was no significant increase in hospital costs. However, 
this could be a paradox, mainly due to the large internal 
variance of collagenase prices. This is especially important 
when one considers that treating three affected joints 
with collagenase costs €7,260 in Spain and €9,204 in UK, as 
compared to €987 for open fasciectomy using local nerve 
block with sedation. The fact that the results do not show 
a significant difference in costs could be due to the large 
variance in the data. If EU prices were more homogenous, 
statistical results could show a significant increase in costs.
In the private hospital setting, treating one, two and three 
affected joints also gave no significant increase in costs 
when compared to open fasciectomy. However, treating 
three affected joints with collagenase injections costs 
nearly three times as much as open fasciectomy. The large 
variance in cost could also be the reason for this result. This 
highlights the need to have more homogenous prices, 
not just between EU member states, but also with other 
countries.
Apart from economic considerations, using CCH injections 
to replace surgery could have other benefits in the Maltese 
healthcare system. The government hospital, falling under 
the responsibility of the Health Ministry and the Finance 
Ministry for budgetary approval, has a responsibility to make 
the best use out of the limited resources available.  
The government is also under pressure from the public to 
reduce the waiting list for surgeries. An article published 
in The Sunday Times of Malta on 27th October 2013 listed 
the Orthopaedics Department as the one with the most 
patients waiting to be given a date for their surgery. 
Most of these patients are waiting for total hip or knee 
replacements. Taking this into consideration, if all patients 
needing open fasciectomy for Dupuytren’s Contracture 
were switched over to CCH injections, an additional twenty 
total knee replacements could be performed every year.
Breakdown of costs Government hospital
Number of joints affected and number of injections 
needed
1 joint,
3 injections
2 joints,
6 injections
3 joints,
9 injections
Cost of injections €231 €462 €693
Number of out-patient visits needed
(at €35 each) 9 15 21
Cost of out-patient visits €315 €525 €735
Total €546 €987 €1,428
Table 1: Cost of treating one, two or three affected joints with collagenase injections at the proposed price (€77 per vial) for the Maltese market
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Conclusion
Collagenase Clostridium histolyticum injections, at the 
prices last available on the market, would not be a cost-
effective option for treating Dupuytren’s Contracture in 
the government hospital. Open fasciectomy in the state 
hospital costs much less than in the private sector mainly 
due to the running costs.
In the private sector, CCH injections are more cost-effective 
than open fasciectomy when only one finger is affected. 
When multiple fingers are affected, open fasciectomy 
remains the least expensive option. At the prices available 
in Europe, using CCH injections in the private sector would 
always be less expensive than surgery if only one finger 
is affected. With open fasciectomy and aftercare costing 
€3,361 per patient, CCH injections would result in savings 
ranging from €88 (if CCH is priced €941 at per vial) up to 
€736 (if CCH is priced at €725 per vial).When two or more 
fingers are affected, the results are reversed. With the cost 
of treating two fingers with CCH injections amounting to a 
minimum of €5,100 (when CCH injections are priced at €725 
per vial), injections would be more expensive than open 
fasciectomy by a minimum of €1,739.
With the majority of patients having one or two fingers 
affected, CCH injections need to be less expensive than 
surgery to be cost-effective, and should ideally cost €77 
or less per vial, to be at an equal cost to surgery in the 
government hospital.
If all patients treated at the government hospital for 
Dupuytren’s Contracture are switched to collagenase 
Clostridium histolyticum injections, the hospital would 
be increasing its expenses, but at the same time it would 
free operating theatre hours that could be used for other 
procedures, thus reducing patients’ waiting lists.
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Disclaimer:
During the initial stages of the study, the corresponding author was 
an employee of Pfizer. At the time, the marketing authorisation for 
collagenase injections had already been sold by Pfizer to Auxilium 
Pharmaceuticals.
Apart from economic considerations, using Clostridium 
histolyticum injections to replace surgery could have 
other benefits in the Maltese healthcare system. 
